Prostacyclin and thromboxane release from human peritoneal macrophages. 1983

M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008689 Methacrylates Acrylic acids or acrylates which are substituted in the C-2 position with a methyl group. Methacrylate
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000001 Calcimycin An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems. 4-Benzoxazolecarboxylic acid, 5-(methylamino)-2-((3,9,11-trimethyl-8-(1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl)-1,7-dioxaspiro(5.5)undec-2-yl)methyl)-, (6S-(6alpha(2S*,3S*),8beta(R*),9beta,11alpha))-,A-23187,A23187,Antibiotic A23187,A 23187,A23187, Antibiotic
D013929 Thromboxane B2 A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin). B2, Thromboxane
D013930 Thromboxane-A Synthase An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5. Thromboxane Synthetase,Thromboxane A Synthase,Thromboxane A2 Synthetase,A2 Synthetase, Thromboxane,Synthase, Thromboxane A,Synthase, Thromboxane-A,Synthetase, Thromboxane,Synthetase, Thromboxane A2
D013931 Thromboxanes Physiologically active compounds found in many organs of the body. They are formed in vivo from the prostaglandin endoperoxides and cause platelet aggregation, contraction of arteries, and other biological effects. Thromboxanes are important mediators of the actions of polyunsaturated fatty acids transformed by cyclooxygenase. Thromboxane
D015121 6-Ketoprostaglandin F1 alpha The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue. 6-Keto-PGF1 alpha,6-Oxo-PGF1 alpha,6-Oxoprostaglandin F1 alpha,6 Ketoprostaglandin F1 alpha,6 Keto PGF1 alpha,6 Oxo PGF1 alpha,6 Oxoprostaglandin F1 alpha,F1 alpha, 6-Ketoprostaglandin,F1 alpha, 6-Oxoprostaglandin,alpha, 6-Keto-PGF1,alpha, 6-Ketoprostaglandin F1,alpha, 6-Oxo-PGF1,alpha, 6-Oxoprostaglandin F1

Related Publications

M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell
November 1981, Journal of the Reticuloendothelial Society,
M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell
January 1987, Circulatory shock,
M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell
March 1981, British journal of pharmacology,
M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell
June 1997, FEBS letters,
M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell
October 1981, The American review of respiratory disease,
M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell
June 1987, FEBS letters,
M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell
January 1982, Advances in experimental medicine and biology,
M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell
December 1989, Circulatory shock,
M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell
May 1981, Nature,
M Foegh, and Y T Maddox, and J Winchester, and T Rakowski, and G Schreiner, and P W Ramwell
April 1991, Circulatory shock,
Copied contents to your clipboard!